slightbourne@noblecapitalmarkets.com, Author at Channelchek

First Hawaiian Is Acquiring TriCo Bancshares to Build the Sixth Largest Western US Bank

Posted on July 13, 2026July 13, 2026 by [email protected]

The community banking consolidation wave just produced one of its most strategically significant deals of the year. First Hawaiian, Inc. (Nasdaq: FHB), parent company of Hawaii’s oldest and largest financial institution, announced today it has entered into a definitive agreement to acquire TriCo Bancshares (Nasdaq: TCBK), parent company of California-based Tri Counties Bank, in an all-stock transaction. The deal creates a combined institution with approximately $34 billion in assets and positions it as the sixth largest bank headquartered in the Western United States.

Under the terms of the agreement, TriCo shareholders will receive 2.095 shares of First Hawaiian common stock for each TriCo share, representing $63.12 per share based on First Hawaiian’s July 10 closing price. Upon completion, First Hawaiian shareholders will own approximately 65% of the combined company and TriCo shareholders approximately 35%. Four current TriCo directors, including CEO Rick Smith, will join First Hawaiian’s board. The transaction is expected to close by the end of 2026, subject to regulatory approvals and shareholder votes from both companies.

Why This Combination Makes Sense

The strategic logic is geographic diversification. First Hawaiian has built a dominant franchise across Hawaii, Guam, and Saipan over its 168-year history, but its mainland presence has been limited. TriCo brings a well-established community banking network throughout California, with deep local market positions, an experienced leadership team, and a strong deposit franchise. The combination gives First Hawaiian a meaningful footprint on the mainland without requiring it to build from scratch in a new market.

Importantly, the two institutions share a similar operating philosophy. Both are relationship-driven, community-focused banks with disciplined credit cultures and strong local reputations. First Hawaiian has committed to retaining the Tri Counties Bank branding on the mainland and has stated there are no expected branch closings associated with the transaction, a signal that the deal is designed to preserve both franchises rather than collapse one into the other.

The Financial Profile of the Combined Company

First Hawaiian released preliminary second quarter results alongside the merger announcement, and the numbers reinforce why the company is in a position to execute an acquisition of this scale. Net income came in at $73.4 million with diluted earnings per share of $0.60, compared to $67.8 million and $0.55 in the prior quarter. Net interest margin expanded six basis points to 3.25%, return on average assets improved to 1.23%, and tangible book value per share grew 3% quarter over quarter to $15.04. Gross loans increased to $14.6 billion from $14.4 billion the prior quarter.

Those are the metrics of a bank operating from a position of strength rather than necessity.

The Broader Community Banking Signal

For investors tracking community and regional banks in the small and microcap space, the First Hawaiian-TriCo deal continues a clear consolidation pattern. Rising funding costs, increasing regulatory burden, commercial real estate exposure, and intensifying competition from larger institutions and fintech platforms are all creating pressure on smaller banks to pursue scale through combination rather than organic growth alone.

The structure of this deal is worth noting. An all-stock transaction with no branch closings, retained branding, shared board representation, and leadership drawn from both organizations reflects a partnership model rather than a hostile takeover. That approach tends to preserve customer relationships and employee retention, both of which are critical for community banks where the value of the franchise is built almost entirely on local trust.

As the cost of remaining independent continues to rise for smaller banking institutions, transactions like this one are likely to become more frequent. The banks that choose their partners wisely and execute clean integrations will be the ones best positioned to compete in an increasingly consolidated landscape.

VivoPower International PLC (VIVO) – Building at the Power Layer of AI Infrastructure

Posted on July 13, 2026July 13, 2026 by [email protected]

Monday, July 13, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating. We are initiating coverage on VivoPower International PLC (NASDAQ: VIVO) with an Outperform rating and $10 Price target. The company has recently pivoted toward acquiring and developing power-secured land and powered-shell data center infrastructure, targeting one of the most constrained inputs in the AI value chain: grid-connected power capacity.

Capital-Light Business Model. The company occupies an upstream position within the AI data center value chain. Rather than owning and operating IT infrastructure, it seeks to generate returns through land development, power procurement, and long-term leasing arrangements. In our view, this model provides exposure to AI infrastructure demand while reducing technology and operating risks.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

T3 Defense (DFNS) – Another Acquisition

Posted on July 13, 2026July 13, 2026 by [email protected]

Monday, July 13, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Acquisition. On Friday, T3 Defense announced the acquisition of a 60% stake in Project35, a leading Israeli developer and manufacturer of drones, aerial interceptors and counter-UAV systems for Tier-1 defense customers in Israel and around the world. The acquisition launches T3 Defense into the center of the fast-expanding drone and counter-UAV (C-UAV) armament market, adding field-proven platforms and a new class of autonomous interceptor to its portfolio.

Terms. Under the terms of the transaction, T3 acquired its stake for 21,059,871 shares of T3 Defense common stock and a 12% promissory note due one day before the anniversary date in the principal amount of $1,250,000. At a current stock price of approximately $0.11, the value of the deal is about $3.56 million. Following closing, T3 Defense expects to work with Project35’s management team to support commercialization, production scaling, and expansion into additional customer programs, in addition to investing $2.5 million directly into the company’s operations over the next 12 months.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Apple Is Suing OpenAI for Trade Secret Theft. The Fallout Could Reshape the AI Hardware Race and Delay the Biggest IPO of the Fall

Posted on July 13, 2026July 13, 2026 by [email protected]

What was once one of the most high-profile partnerships in technology has turned into one of its most explosive legal battles. Apple filed a federal trade secret lawsuit against OpenAI on July 10 in the Northern District of California, alleging that the AI company orchestrated a systematic campaign to steal confidential hardware designs, supplier information, and product specifications through former Apple employees. The complaint also names io Products, the hardware design firm co-founded by former Apple design chief Jony Ive that OpenAI acquired last year.

The allegations are not subtle. Apple’s filing describes a coordinated effort at every level of OpenAI’s organization to acquire proprietary information about unreleased Apple hardware products. The two former employees at the center of the case are Tang Tan, who served as a vice president at Apple before becoming OpenAI’s Chief Hardware Officer, and engineer Chang Liu, who Apple alleges departed with an unreturned company laptop and exploited a software bug that gave him continued access to Apple’s internal file servers after his departure. Apple further claims that OpenAI interviewers encouraged job candidates to bring Apple prototypes and physical components to interviews as part of the hiring process.

OpenAI has denied the allegations, stating that the company has no interest in other companies’ trade secrets and remains focused on building its own technology.

From Partners to Adversaries

The lawsuit represents a dramatic reversal in the relationship between the two companies. As recently as mid-2025, Apple and OpenAI were working together to integrate ChatGPT into Apple’s software platforms and Siri digital assistant. That partnership has since dissolved entirely. In January 2026, Apple announced it was turning to Google for its Apple Intelligence initiatives, and the companies have been moving in increasingly competitive directions ever since, particularly in the emerging AI hardware device market.

The timing of Apple’s filing is significant for reasons beyond the legal merits. OpenAI confidentially filed for an IPO earlier this summer at a reported valuation of $730 billion to $850 billion, with Goldman Sachs and Morgan Stanley leading the offering. A trade secret lawsuit of this magnitude, filed by the most valuable company in the world, introduces material uncertainty into that process. Discovery alone could force OpenAI to disclose internal communications and hardware development timelines that it would strongly prefer to keep private during a pre-IPO quiet period.

The Three-Way AI Rivalry Deepens

The Apple-OpenAI conflict does not exist in isolation. It is playing out against the backdrop of an intensifying three-way rivalry between Apple, OpenAI, and SpaceX, whose CEO Elon Musk co-founded OpenAI before leaving and eventually launching the competing xAI platform. Musk weighed in immediately after the lawsuit was filed, and the public back-and-forth between Musk and OpenAI CEO Sam Altman escalated over the weekend as both companies simultaneously released competing AI models.

SpaceX completed its record $75 billion IPO in June and is pursuing a $60 billion acquisition of AI coding company Cursor. OpenAI is preparing its own public offering. Apple is navigating a CEO transition as Tim Cook prepares to step down later this year. All three companies are competing aggressively for AI talent, hardware capabilities, and market positioning at the same time.

What It Means for the Broader AI Ecosystem

For investors tracking the AI sector, particularly smaller companies operating in the hardware, semiconductor, and AI infrastructure space, the Apple-OpenAI dispute carries practical implications. If the lawsuit slows or disrupts OpenAI’s hardware ambitions, the competitive landscape for AI device development shifts. Smaller companies building AI edge hardware, consumer AI devices, and specialized components could find themselves operating in a market where one of the most well-funded competitors is legally constrained from executing its product roadmap on the original timeline.

The AI hardware race just became a legal battle. How it resolves will shape competitive dynamics across the sector for years.

The 30-Year Treasury Just Paid Its Highest Yield Since 2007. Here’s What the Auction Actually Showed

Posted on July 13, 2026July 13, 2026 by [email protected]

The U.S. government sold $25 billion of 30-year Treasury bonds yesterday at a yield of 5.058%, the richest rate on a long bond auction since 2007. That headline number is drawing attention, but the full picture from this week’s auctions is more balanced than the yield alone suggests.

Start with the demand side. Pre-auction trading had the 30-year yield sitting at 5.061% just before the bidding deadline, meaning the final result actually came in slightly better than the market was pricing, a sign that buyers stepped in rather than stepped back. That is generally read as a healthy outcome, not a warning sign. Context matters here too. Existing 30-year bonds have already traded as high as 5.20% earlier this year, so yesterday’s print sits within a range the market has already absorbed rather than representing new, uncharted territory.

A day earlier, the Treasury auctioned $42 billion of 10-year notes, and that result was cleaner still. The auction cleared at 4.58% with a bid-to-cover ratio of 2.59, comfortably above the 2.5 level traders typically use as a benchmark for solid demand. No stress signals, no last-minute yield spike, no indication that investors are hesitant to hold U.S. government debt at current levels. Between the two auctions, the government raised $67 billion this week alone as part of a broader $119 billion week of coupon issuance, and both sales found willing buyers.

The interesting nuance is why the 30-year yield moved more than the 10-year. When the long end of the curve carries a higher premium relative to shorter maturities, it typically reflects investors asking for more compensation to hold debt across multiple decades rather than any concern about near-term credit risk. That’s consistent with straightforward supply and demand dynamics: more long-duration issuance generally requires a higher yield to clear the market, independent of the government’s underlying fiscal position.

The practical relevance for investors runs in a few directions. The 10-year yield is the direct reference point for 30-year mortgage rates, so a 4.58% clearing yield keeps the housing affordability conversation roughly where it has been. For companies that borrow against Treasury benchmarks, and smaller, more leveraged businesses in particular tend to feel rate moves more directly, the cost of long-term borrowing is shaped as much by auction dynamics like these as by anything the Federal Reserve decides at its policy meetings. The Fed sets the front end of the curve through its rate decisions. The long end responds to a separate set of forces, including how much duration the market is being asked to absorb and at what price investors are willing to hold it.

Taken together, this week’s auctions showed a market that is functioning and finding demand, just at a higher price for long-duration debt than it has required in nearly two decades. Whether that becomes a durable new range or eases as issuance patterns shift is something the next several auction cycles will help clarify.

SK Hynix Just Completed the Biggest Foreign IPO in U.S. History. It Jumped 14% on Day One

Posted on July 10, 2026July 10, 2026 by [email protected]

SK Hynix began trading on the Nasdaq this morning, and the market’s answer to seven-times oversubscribed demand was immediate. Shares opened at $170, up 14% from the $149 offer price, and were trading as much as 16.7% higher intraday under the temporary ticker SKHYV before the stock moves to its permanent symbol, SKHY, on Monday.

The final numbers on the raise came in at $26.5 billion, slightly below the roughly $28 billion initially targeted but still enough to make this the largest first-time listing by a foreign company in U.S. history, surpassing Alibaba’s American debut. The offering consisted of 177.9 million American depositary receipts, each representing one-tenth of a common share.

The scale of demand tells the real story here. SK Hynix’s South Korea-listed shares have climbed 174% over the past six months and 634% over the past year, and the company’s SEC filing disclosed it now holds 56.4% of the global high-bandwidth memory market, the largest share among the three companies, Micron, Samsung, and SK Hynix, that make this specialized chip. HBM sits directly next to AI processors like Nvidia’s GPUs, holding the data those chips need instantly rather than forcing them to reach across a data center for it. Every major AI buildout depends on it, and there currently isn’t enough to go around.

That shortage, according to industry estimates cited in today’s coverage, could persist into 2030 simply because new fabrication capacity takes years to bring online. It is precisely what SK Hynix’s listing is designed to help fix. Proceeds are earmarked for new manufacturing facilities and equipment, giving U.S. investors a rare direct stake in a name that has mostly been accessible only through Seoul-listed shares.

But the timing carries its own tension. Just three days before this debut, memory stocks including Micron, Samsung, and SK Hynix itself slid into a bear market, a reminder that this industry has a well-earned reputation for violent cycles. Patrick Moorhead, founder of Moor Insights & Strategy, put it bluntly, noting that memory makers were selling chips below cost with negative gross margins only a few years ago before capital expenditure pulled back sharply and demand caught fire again. Micron has responded by locking customers into five-year strategic supply agreements with large upfront payments, a structural shift from the one-year contracts that used to define the industry, aimed at smoothing out exactly this kind of boom-and-bust pattern. Whether that holds the next downturn at bay is an open question nobody can answer yet.

For small and micro-cap investors, SK Hynix itself is now a trillion-dollar company well outside that world. But the moment matters anyway. When the second-largest foreign listing in U.S. history debuts to a 14% pop just days after its own sector fell into bear market territory, it captures the exact push and pull defining the memory trade in 2026: extraordinary current profitability sitting on top of an industry that has never once avoided the cycle eventually turning. The public companies feeding into this supply chain, from equipment makers to specialty materials suppliers, are all trading in that same shadow today.

AZZ (AZZ) – First Quarter FY27 Financial Results Exceed Expectations; Increasing Estimates

Posted on July 10, 2026July 10, 2026 by [email protected]

Friday, July 10, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2027 first quarter financial results. AZZ reported adjusted net income of $55.8 million, or $1.85 per share, compared to $53.8 million, or $1.78 per share, during the prior year period. We had forecast adjusted net income of $51.4 million or $1.70 per share. Compared to the first quarter of FY 2026, sales increased 6.3% to $448.5 million. Adjusted EBITDA amounted to $99.5 million compared to our estimate of $96.8 million. Compared to the prior year period, first quarter Metal Coatings sales were up 12.3% to $210.3 million, while Precoat Metal sales increased 1.5% to $238.2 million. First quarter segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 21.7% for Precoat Metals.

FY 2027 Corporate Guidance. Management now expects FY 2027 sales in the range of $1.80 to $1.85 billion, compared to previous expectations of $1.725 to $1.775 billion. Adjusted EBITDA is expected to be in the range of $375 to $415 million, compared to prior guidance of $360 to $400 million. Adjusted EPS is now projected to be $6.75 to $7.15 versus prior expectations of $6.50 to $7.00.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

The Magnificent 7 Just Hit Their Cheapest Valuation in Over a Decade

Posted on July 10, 2026July 10, 2026 by [email protected]

For most of the past five years, the Magnificent Seven traded at a persistent and widening premium to the rest of the S&P 500. That premium has now compressed to its lowest level in more than a decade, and the implications for how capital flows through the broader market are significant.

The price-to-earnings multiple premium for the Magnificent Seven relative to the other 493 companies in the S&P 500 has dropped to approximately 10%, according to Morgan Stanley. That figure held above 30% for most of the 2020s. The collapse in relative valuation is not because these companies are struggling operationally. It is because the market is repricing what it is willing to pay for growth when that growth comes at the cost of massive, accelerating capital expenditure with uncertain near-term returns.

What’s Driving the Compression

All seven stocks have underperformed the S&P 500 in 2026 except Alphabet, which has gained 14.5% year to date versus the benchmark’s 8.8% advance. Nvidia, Microsoft, Amazon, Meta, Apple, and Tesla have all lagged the index. For a group that dominated market leadership for the better part of three years, the collective underperformance is striking.

The primary source of investor frustration is capital spending on artificial intelligence infrastructure. The Magnificent Seven’s combined AI-related capital expenditures are projected to exceed $700 billion in 2026, a 70% increase from the prior year. That level of spending is consuming corporate cash generation at a pace that has pushed the group’s collective 12-month forward free cash flow projections sharply below their 2024 peak. Investors are watching these companies pour hundreds of billions into data centers and GPUs while the revenue return on that investment remains difficult to quantify with precision.

Layer on the prospect of a Fed rate hike later this year, which would increase the cost of financing AI projects, and the math behind the underperformance becomes straightforward. Higher rates, lower free cash flow, and uncertain AI monetization timelines are a combination that compresses multiples regardless of how strong the underlying business remains.

The Mirror Image for Small Caps

What makes this data point particularly relevant for ChannelChek’s audience is what happens to the rest of the market when the Magnificent Seven’s gravitational pull weakens. For most of 2023 and 2024, the concentration of capital in seven stocks starved the rest of the equity universe of institutional attention and flows. The top ten companies in the S&P 500 grew to represent more than 35% of the index’s total weight, up from 18% a decade ago. That concentration meant the other 493 companies, and the thousands of smaller companies outside the index entirely, were competing for a shrinking share of investor capital.

That dynamic is now reversing. The Russell 2000 posted its best first half in 35 years, gaining nearly 22% through June. Market breadth has expanded meaningfully, with advancing stocks consistently outnumbering decliners. The equal-weight S&P 500 has outperformed the cap-weighted version. Capital that was previously locked into mega cap technology is rotating into industrials, consumer companies, energy producers, and the broader small cap universe.

The Magnificent Seven premium compressing to 10% is the quantitative proof of what the price action has been saying all year. The trade that dominated markets for the past three years is losing its hold, and the beneficiaries are the companies that were left behind during the concentration era. Many of those companies trade well below the $2 billion market cap threshold and are only now beginning to see the valuation and capital flow benefits of a broadening market.

The Magnificent Seven are not broken. They are just no longer the only game in town. For investors positioned in the rest of the market, that is exactly the environment they have been waiting for.

Wall Street Is Finally Noticing Small Caps

Posted on July 9, 2026July 9, 2026 by [email protected]

JPMorgan announced this week that it is building a new investment banking team dedicated entirely to small-cap dealmaking, targeting companies valued between $100 million and $500 million. The team will sit alongside the bank’s existing middle-market group, which covers companies between $500 million and $1 billion and already employs nearly 400 bankers. According to an internal memo reported by Yahoo Finance, the new group will be based in New York, Los Angeles, Dallas, Chicago, and Atlanta, with plans to hire more than 75 bankers in the near term. It will start by focusing on diversified industries, consumer and retail, and business services, led by new hire Michael Flynn, a veteran middle-market banker.

It is a notable move for a bank of JPMorgan’s size. But for investors who have been paying attention to small and micro caps all year, this is a confirmation, not a discovery.

The Russell 2000 gained nearly 22% in the first half of 2026, its best first-half performance since 1991, outpacing the S&P 500 and Dow’s roughly 9% gains and the Nasdaq’s 13% rise. Every sector in the index finished the first half in positive territory, led by technology, industrials, financials, and healthcare. Analysts have pointed to easing financial conditions, a healthier credit backdrop, and valuations that remain meaningfully discounted relative to large caps as reasons the rally has legs. Small caps also tend to benefit disproportionately once a rate-cutting cycle takes hold, since a larger share of their balance sheets rely on variable or shorter-term financing.

What JPMorgan’s move really signals is that the largest pools of capital are starting to reposition toward a part of the market that has been overlooked for the better part of a decade. Big banks do not build out dedicated coverage teams on a whim. They do it when deal flow, IPO activity, and client demand justify the headcount, and that kind of infrastructure typically follows smart money into a space rather than leading it there.

That kind of institutional attention tends to arrive with real consequences for pricing. More bankers covering the space usually means more IPOs, more M&A activity, more equity research, and ultimately more liquidity flowing into names that have traded at a discount simply because fewer people were watching them closely. Small caps have historically underperformed for years at a time before snapping back sharply once capital rotates in, and that rotation is often driven by exactly this kind of institutional repositioning rather than a single catalyst.

For investors, the takeaway is straightforward. Institutional capital chasing small caps tends to compress the valuation gap that made the space attractive in the first place. Getting positioned ahead of that convergence, rather than after it, is where the real opportunity sits. With small caps already outperforming and now drawing this kind of attention from a bank the size of JPMorgan, the window to act on that discount looks like it will not stay open indefinitely.

MAIA Biotechnology (MAIA) – First Data From Phase 2 Part C Trial Shows Data Consistent With Earlier Studies

Posted on July 9, 2026July 9, 2026 by [email protected]

Thursday, July 09, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data From Part C Announced. MAIA announced data from Part C (Expansion stage) of its Phase 2 THIO-101 trial in non-small cell lung cancer (NSCLC). This open-label stage of the trial tests the combination of ateganosine and cemiplimab (Libtayo, from Regeneron) as a third-line (3L) therapy for patients with advanced disease that no longer respond to other therapies. The data after the first evaluation have a Disease Control Rate (DCR) of 90.5% (19 out of 21 patients), compared with published rates of 25% to 35%. We view this as a good sign that patient responses are consistent with previous data.

Design Of the Phase 2 THIO-101 Trial. The Phase 2 THIO-101 Expansion stage is the third part of the Phase 2 trial. Part A tested safety, while Part B was for dose optimization and selection. Part C is currently testing the combination of the 180 mg dose of ateganosine with cemiplimab. If positive, the data could be used to apply for accelerated approval from the FDA.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

AZZ (AZZ) – First Quarter FY27 Financial Results Exceed Expectations; Guidance Raised

Posted on July 9, 2026July 9, 2026 by [email protected]

Thursday, July 09, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

FY 2027 First Quarter Financial Results. AZZ reported adjusted net income of $55.8 million, or $1.85 per share, compared to $53.8 million, or $1.78 per share, during the prior year period. We had forecast adjusted net income of $51.4 million or $1.70 per share. Compared to the first quarter of FY 2026, sales increased 6.3% to $448.5 million. Adjusted EBITDA amounted to $99.5 million compared to our estimate of $96.8 million. Compared to the prior year period, first quarter Metal Coatings sales were up 12.3% to $210.3 million, while Precoat Metal sales increased 1.5% to $238.2 million. First quarter segment adjusted EBITDA margin amounted to 30.3% for Metal Coatings and 21.7% for Precoat Metals.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Why the Fed’s July Meeting Matters More for Small Caps Than Anyone Else

Posted on July 9, 2026July 9, 2026 by [email protected]

The Russell 2000 has gained 33.8% over the past twelve months, comfortably beating the S&P 500’s 20% return, and just posted its best first-half performance since 1991. That’s the headline every small-cap investor has been celebrating. The number underneath it tells a different story.

Interest expense now consumes 31% of EBITDA for companies in the Russell 2000, the heaviest debt-servicing burden these companies have carried in at least six years. Nearly 30% of small-cap corporate debt sits on floating rates, meaning it resets with whatever the Federal Reserve does next rather than staying locked in at yesterday’s borrowing costs. By comparison, floating-rate debt makes up only about 7% of S&P 500 balance sheets, and large-cap interest expense sits at just 6.7% of EBITDA. Small caps have always carried more leverage relative to earnings than their large-cap counterparts. What’s changed is how expensive that leverage has become to service, and how much more exposed small caps are to the Fed’s next move than the rest of the market.

The mechanics here matter more for small caps than almost anywhere else in the market. Large-cap companies tend to term out their debt for years at fixed rates and carry investment-grade credit ratings that keep borrowing costs manageable even when the Fed holds rates higher for longer. Small caps don’t have that luxury. They borrow shorter, they borrow at higher spreads to begin with, and a much larger share of that borrowing floats with prevailing rates. When the Fed moves, small-cap balance sheets feel it first and feel it hardest.

That’s exactly why this rally has been happening in a market environment that should, in theory, be working against it. The Fed under Chair Kevin Warsh has taken a notably hawkish posture this year, and traders have spent recent months pricing in the possibility of an actual rate increase rather than the cuts most investors expected heading into 2026. Small caps have rallied anyway, which tells you the earnings growth story has been strong enough to outrun the rate pressure so far.

The risk is what happens if that earnings momentum slows while rates stay elevated or move higher. A company with debt priced at a wide spread over a floating benchmark doesn’t get relief just because its revenue is growing. If margins compress at all, from wage inflation, input costs, or slowing demand, the interest bill doesn’t shrink to match. It’s the same amount of debt service pulled from a smaller pool of operating income, and at 31% of EBITDA already, there isn’t a lot of room to absorb a shock before it starts showing up in earnings per share. Nearly 40% of Russell 2000 companies are already unprofitable, which leaves a meaningful chunk of the index with even less cushion.

The Fed’s next meeting lands July 28-29, and it’s arguably a more important date for small-cap investors than for the broader market. A hold or a dovish tone gives the current rally room to keep running. A hike, or even language that keeps a hike on the table for the fall, tightens the exact pressure point that’s already the most fragile part of the small-cap balance sheet. For anyone riding this year’s small-cap strength, the momentum is real, but so is the leverage sitting underneath it.

Chemomab and Scipher Merge to Bring AI-Guided Precision Medicine to Rheumatoid Arthritis

Posted on July 8, 2026July 8, 2026 by [email protected]

Two small-cap biotechs are betting that artificial intelligence can succeed where a decade of drug development has stalled. Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine announced this morning that they have entered into a definitive merger agreement, combining Chemomab’s clinical-stage antibody nebokitug with Scipher’s AI-powered precision medicine platform to attack rheumatoid arthritis from a completely different angle than anything currently on the market.

The numbers explain why this matters. No new mechanism of action has been approved for rheumatoid arthritis since 2012, and no new branded therapy has reached the market since 2019. Only about a third of RA patients achieve low disease activity on current treatments, and the two leading drug classes now carry FDA boxed warnings. It’s a $24 billion market that has effectively been standing still for over a decade while patients cycle through drugs that only partially work.

Chemomab’s contribution is nebokitug, a first-in-class antibody that blocks CCL24, a protein tied to both inflammation and fibrosis. That dual mechanism is the differentiator. Most RA drugs on the market today only address inflammation, leaving the fibrotic, tissue-scarring side of the disease untouched. Nebokitug has already produced positive results across five clinical trials, including a Phase 2 study in primary sclerosing cholangitis that hit its safety endpoint and improved a range of fibrosis-related markers.

Scipher brings the half of the equation that makes this deal genuinely interesting. The company’s AI Network Medicine platform independently ranked CCL24 as the top therapeutic target for RA, arriving at the same conclusion Chemomab had reached through years of bench research, but from a completely different direction. Scipher also owns PrismRA, the only rheumatoid arthritis test with Medicare and Medicaid reimbursement approval for predicting how a patient will respond to treatment. That test will be used to select patients for the upcoming Phase 2 trial, meaning the study isn’t just testing whether nebokitug works. It’s testing whether AI-selected patients respond better than an unselected population, which is precisely the kind of precision-medicine proof point regulators and physicians have been waiting for.

Under the deal terms, the combined company will operate as Scipher Medicine Corporation and trade under the ticker SCIP. Scipher shareholders will hold roughly 68% of the combined entity, with Chemomab shareholders holding about 32% plus contingent value rights tied to nebokitug milestones. A syndicate led by Northpond Ventures, with Khosla Ventures, Blue Owl Healthcare Opportunities, and Neuberger funds participating, is putting in $30 million to fund the combined company. That capital, together with existing cash, is expected to carry operations into the second half of 2028, well past the Phase 2 readout expected in the first half of that year.

The deal values the combined company at $150 million before the new financing, a modest figure for a company sitting on a potential first-in-market precision medicine therapy for a disease affecting more than 20 million people worldwide. Scipher also brings existing revenue through biopharma partnerships and its immunology data business, giving the combined company more than one path to funding its pipeline while the RA trial plays out.

The transaction still needs shareholder approval from both companies and an SEC-cleared S-4 registration statement, with closing targeted for the fourth quarter of 2026.